ストックスクリーナーアプリを入手
0.8659
3.32%
0.0278
前日終値:
$0.8381
開ける：
$0.82
24時間の取引高:
165.88K
Relative Volume:
1.16
時価総額：
$44.98M
収益：
-
当期純損益:
$-51.47M
株価収益率:
-0.8659
EPS:
-1
ネットキャッシュフロー:
$-47.50M
1週間 パフォーマンス:
-1.90%
1か月 パフォーマンス:
-13.41%
6か月 パフォーマンス:
-46.22%
1年 パフォーマンス:
-59.73%
1日の値動き範囲:
$0.81
$0.88
1週間の範囲:
$0.81
$0.91
52週間の値動き範囲:
$0.81
$2.215
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
名前
Pmv Pharmaceuticals Inc
セクター
電話
(609) 642-6670
住所
400 ALEXANDER PARK DRIVE, PRINCETON
PMVP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
0.8659 | 45.86M | 0 | -51.47M | -47.50M | -1.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-05-13 | 開始されました | Craig Hallum | Buy |
| 2024-04-12 | 開始されました | Jefferies | Buy |
| 2023-12-27 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-03-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-09-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-08-19 | 開始されました | Oppenheimer | Perform |
| 2021-08-02 | 開始されました | Guggenheim | Buy |
| 2021-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-10-20 | 開始されました | Cowen | Outperform |
| 2020-10-20 | 開始されました | Evercore ISI | Outperform |
| 2020-10-20 | 開始されました | Goldman | Neutral |
すべてを表示
Pmv Pharmaceuticals Inc (PMVP) 最新ニュース
PMVP Advances PYNNACLE Trial with Steady Enrollment | PMVP Stock News - GuruFocus
PMV Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights | PMVP Stock News - GuruFocus
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire
PMVP Reports First Quarter Cash Position and Operational Spendin - GuruFocus
Randy A. Bowman Appointed Chairman of the Board at Westwood Holdings Group - The Manila Times
PMV Pharmaceuticals Reports Progress in Phase 2 PYNNACLE Trial and First Quarter 2025 Financial Results - Nasdaq
JPMorgan Chase & Co. Buys 23,559 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
In the Green: PMV Pharmaceuticals Inc (PMVP) Closes at 0.87, Up/Down -7.34 from Previous Day - DWinneX
PMV Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Sells 11,052 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
JPMorgan Chase & Co. Buys 336,516 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
PMV Pharmaceuticals stock hits 52-week low at $1.32 - MSN
ConocoPhillips (NYSE:COP) Receives Average Recommendation of “Buy” from Analysts - American Banking and Market News
APA Group (OTCMKTS:APAJF) Stock Price Down 9.1% – Here’s What Happened - Defense World
XP Power (OTCMKTS:XPPLF) Trading Down 12% – Should You Sell? - Defense World
PMV Pharmaceuticals (NASDAQ:PMVP) Stock Price Down 3.7% – Should You Sell? - Defense World
Dunxin Financial (NYSEAMERICAN:DXF) Stock Price Up 5.6% – Here’s What Happened - Defense World
Molecular Partners (OTCMKTS:MLLCF) Shares Down 1.4% – Should You Sell? - Defense World
PMV Pharmaceuticals patents new TP53 stabilizers - BioWorld MedTech
Alterome Therapeutics Announces New Chief Executive Officer and Chair of the Board of Directors - Business Wire
Promising Biotech Stocks To Watch Now – April 6th - Defense World
PMVP stock touches 52-week low at $1.01 amid market challenges - Investing.com Australia
PMV Pharmaceuticals stock hits 52-week low at $1.2 amid market shifts - Investing.com
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HC Wainwright Reiterates “Buy” Rating for PMV Pharmaceuticals (NASDAQ:PMVP) - Defense World
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
PMVP stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
PMVP stock touches 52-week low at $1.2 amid market challenges By Investing.com - Investing.com South Africa
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing - Nasdaq
PMV Pharmaceuticals Reports Progress in Clinical Trials - TipRanks
PMV Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PMV Pharmaceuticals stock hits 52-week low at $1.32 By Investing.com - Investing.com South Africa
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
PMV Pharmaceuticals (PMVP) Expected to Announce Quarterly Earnings on Thursday - Defense World
3 US Penny Stocks To Consider In February 2025 - simplywall.st
PMV Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Perceive Pharma: $15 Million (Series A) Raised For Advancing Ophthalmic Neuroprotection - Pulse 2.0
PMVP Stock Sees Surge of Approximately 2.86% in Last Five Days - Knox Daily
Catalio Capital Management Joins $15 Million Series A for Perceive Pharma - citybiz
Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection - PR Newswire
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Significant Drop in Short Interest - MarketBeat
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results - br.ADVFN.com
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire
Pmv Pharmaceuticals Inc (PMVP) 財務データ
収益
当期純利益
現金流量
EPS
Pmv Pharmaceuticals Inc (PMVP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mack David Henry | President and CEO |
Jan 03 '25 |
Option Exercise |
0.53 |
17,709 |
9,386 |
551,919 |
| Jalota Deepika | Chief Development Officer |
Sep 11 '24 |
Sale |
1.50 |
7,218 |
10,853 |
118,283 |
| Carulli Michael | Chief Financial Officer |
Sep 11 '24 |
Sale |
1.50 |
2,891 |
4,347 |
88,395 |
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):